Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23801987 | 0.75 | RECQL (0.40) | MAPTTSHRALDH1A1HPGDNPC1 | |
| SCHEMBL20380129 | 0.75 | ALDH1A1 (0.39) | MAPTALDH1A1HPGDNPC1MEN1 | |
| SCHEMBL6263190 | 0.75 | ALDH1A1 (0.44) | MAPTALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL7443658 | 0.74 | PDE4A (0.38) | MAPTTSHRNPC1PTGS2MEN1 | |
| SCHEMBL14380637 | 0.70 | CTRB1 (0.35) | MAPTTSHRALDH1A1HPGDMEN1 | |
| SCHEMBL6265155 | 0.69 | ALDH1A1 (0.40) | MAPTALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL2474471 | 0.68 | ALDH1A1 (0.55) | MAPTALDH1A1HPGDNPC1MEN1 | |
| SCHEMBL3035436 | 0.68 | ALDH1A1 (0.45) | MAPTTSHRALDH1A1HPGDNPC1 | |
| SCHEMBL2471687 | 0.68 | PDE4A (0.59) | — | |
| SCHEMBL27189777 | 0.67 | ACHE (0.43) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | ITGB1, ITGAV, ITGA1 | MAPT 4388/4885TSHR 2176/4885ALDH1A1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.